Metformin and rapamycin

Short answer

Metformin and rapamycin are the best-known pharmaceutical longevity candidates. Rapamycin robustly extends lifespan in mice, including when started late in life, while metformin's case rests on diabetes outcomes and confounded observational data. Neither drug has a completed human lifespan trial, and the definitive metformin trial, TAME, is still not recruiting, so both sit at promising rather than proven.

Summary drafted from this entry’s sources; editorial review pending.

01Key questions

Does rapamycin extend human lifespan?

No one knows. It extends lifespan in mice even when started late in life, but the human data is small studies on immune, skin and vaccine-response endpoints plus off-label clinic use.²³

Does metformin slow aging?

Unproven. Diabetic cohorts sometimes show lower mortality and cancer on metformin, but confounding is severe, and the TAME trial designed to test aging directly remains pre-recruitment.¹⁴⁵

What are the side effects?

Metformin causes GI upset and depletes B12 with long-term use; rapamycin causes mouth ulcers, can raise lipids and glucose, and impairs wound healing. Rapamycin also interacts strongly with CYP3A4 inhibitors like grapefruit.³

Should healthy people take either?

The body's own framing: metformin fits best when insulin resistance is actually present, and rapamycin at most as a clinician-supervised experiment. Neither substitutes for training, sleep or visceral-fat reduction.

What would change this rating?

TAME completing for metformin, and any large randomized trial of intermittent rapamycin in healthy adults using clinical rather than biomarker endpoints.¹

Core thesis: Metformin and rapamycin are the two best-known pharmaceutical geroscience candidates, but they sit in very different evidence buckets. Rapamycin has unusually strong lifespan-extension data across model organisms and genetically heterogeneous mice, while metformin has decades of human safety data and suggestive disease-risk associations. Neither is proven to extend lifespan in healthy humans.

02Evidence at a Glance

Intervention	Main Pathway	Strongest Evidence	Human Longevity Evidence	Main Caution
Metformin	Complex I inhibition → AMPK, lower hepatic glucose output, insulin signaling changes	Diabetes outcomes, observational associations, mechanistic geroscience	TAME rationale; no completed definitive aging RCT	GI effects, B12 depletion, exercise-adaptation controversy
Rapamycin / sirolimus	mTORC1 inhibition, autophagy, protein synthesis restraint, immune remodeling	Robust mouse lifespan extension including late-life start	Small immune/skin/periodontal studies; off-label practice; no definitive lifespan trial	Mouth ulcers, lipids, glucose, wound healing, drug interactions

Swipe table →

03Metformin

Mechanism of Action

Metformin is often described as an AMPK activator, but the upstream picture matters:

Mitochondrial Complex I inhibition can shift cellular energy state, raising AMP/ATP and activating AMPK-linked programs.
Hepatic glucose production falls, improving fasting glucose and insulin exposure in type 2 diabetes.
Gut effects may be central: bile-acid signaling, microbiome changes, GLP-1 effects, and intestinal glucose handling.
Inflammatory and cancer-related signaling may shift indirectly through insulin, mTOR, NF-κB, and metabolic state.

The first-principles interpretation: metformin is not a magic anti-aging molecule; it is a metabolic stressor that can improve an overfed/insulin-resistant terrain. In already insulin-sensitive, highly active people, the benefit-to-noise ratio is less clear.

Longevity Evidence

Important evidence anchors:

PMID: 27304507 — Barzilai et al., Metformin as a Tool to Target Aging, outlines the rationale for TAME and aging-as-a-target trial design.
Observational diabetic cohorts sometimes show lower cancer/CVD/mortality risks among metformin users, but confounding by indication, immortal-time bias, comparator choice, and diabetes severity are major issues.
Animal data are mixed and context-dependent. Some mouse studies show benefit; dose, strain, sex, age at initiation, and diet matter.
TAME Trial is conceptually important because it attempts to test a composite of age-related outcomes rather than one disease silo.

Exercise Interference Debate

A recurring concern is that metformin may blunt some exercise adaptations, especially mitochondrial and cardiorespiratory improvements in older adults. This does not mean “never combine metformin and exercise.” It means metformin should not be casually added to a healthy athlete's protocol without a reason such as impaired glucose control.

Practical interpretation:

If glucose/insulin markers are poor, metformin may improve the metabolic floor.
If VO₂max, strength, and insulin sensitivity are already excellent, the marginal longevity benefit is unknown.
Training remains a higher-confidence intervention than metformin for most non-diabetic people.

Uses

Strategy	Notes
Studies started low	Reduces GI intolerance
Common metabolic dose	More relevant for diabetes/insulin resistance than speculative longevity
Extended release	Often better tolerated
Training-sensitive use	Speculative but reasonable if performance is the main goal

Swipe table →

Side Effects and Contraindications

GI distress: diarrhea, nausea, cramping; slower titration and ER formulation help.
Vitamin B12 depletion: monitor B12, methylmalonic acid, homocysteine if long-term use.
Renal function: avoid or use strict medical guidance with severe renal impairment; lactic acidosis is rare but serious.
Acute illness/surgery/contrast: temporary holds may be appropriate under clinician guidance.

04Rapamycin / Sirolimus

Mechanism of Action

Rapamycin binds FKBP12 and inhibits mTORC1, a nutrient-sensing complex that promotes growth, translation, lipid synthesis, and anabolic signaling. Intermittent mTORC1 inhibition can increase Autophagy, reduce some senescence-associated signaling, and shift immune function. Chronic or high exposure may also affect mTORC2, which is more associated with insulin resistance and adverse metabolic effects.

The central Heretic question is not “is mTOR good or bad?” It is whether timed, partial mTORC1 inhibition can preserve repair and stress resistance without chronically suppressing growth, immune competence, glucose handling, or wound healing.

Longevity Evidence

Rapamycin is the flagship pharmacologic result from the NIA Interventions Testing Program:

PMID: 19587680 — Harrison et al. 2009 showed that rapamycin started late in life extended lifespan in genetically heterogeneous mice.
Follow-up ITP studies found sex-, dose-, and protocol-dependent effects.
Benefits have been reported across yeast, worms, flies, and mice, but model-organism conservation does not automatically prove human lifespan extension.
PMID: 40620657 reviews the modern longevity debate, off-label use, and translational gaps.

Human Data: What Exists and What Does Not

What exists:

FDA-approved clinical experience with sirolimus/everolimus in transplant and tuberous sclerosis contexts.
Small studies using rapalogs for immune function, vaccine response, dermatologic aging markers, and disease-specific endpoints.
Growing off-label physician experience in longevity clinics.

What does not exist:

A completed, large, long-duration RCT showing lifespan extension in healthy humans.
Consensus dosing for prevention.
Long-term safety data for decades of intermittent use in healthy people.

Uses

Example Range	Rationale	Main Monitoring
—	Favor mTORC1 pulses, avoid chronic immunosuppression	CBC, CMP, A1c/glucose, fasting insulin, lipids
—	Lower side-effect risk; uncertain efficacy	Same, plus symptom tracking
—	More pharmacologically continuous; used by some clinicians	More concern for mTORC2/metabolic effects
—	Attempts to balance autophagy and recovery	Track wounds, infections, oral ulcers

Swipe table →

Do not combine casually with strong CYP3A4/P-gp inhibitors such as grapefruit, ketoconazole-class antifungals, some macrolides, and certain HIV/HCV drugs. Blood levels can change dramatically.

Side Effects and Risk Signals

Mouth ulcers/stomatitis: common practical limiter.
Lipids: LDL/triglycerides may rise.
Glucose: insulin resistance or higher glucose can occur, especially with chronic exposure.
Wound healing: avoid around surgery, acute injuries, dental procedures, or tissue-repair phases.
Infection risk: lower intermittent doses may differ from transplant dosing, but immune effects still require respect.
Fertility/reproductive signaling: mTOR is central to growth and reproduction; avoid in pregnancy and when trying to conceive unless medically directed.

05Combined or Sequential Use

Some animal studies and longevity clinics discuss combining metformin and rapamycin because they touch nutrient-sensing from different angles: AMPK/insulin and mTOR/autophagy. This is mechanistically plausible but not proven as a healthy-human protocol.

Potential logic:

Use metformin when the metabolic phenotype is insulin resistant or hyperglycemic.
Use rapamycin, if at all, as an intermittent stress-resistance/autophagy signal rather than chronic suppression.
Do not stack drugs to compensate for poor sleep, high visceral fat, low muscle mass, or no training.
Measure whether the intervention improves the phenotype it was chosen for.

06Natural Mimetics and Adjacent Compounds

Per the dietary-restriction-mimetic literature, several natural compounds partly overlap with AMPK/mTOR biology. These are weaker and dirtier than the drugs, but may fit better for low-risk experimentation.

Compound	Proposed Overlap	Evidence Caveat
Berberine	AMPK/glucose lowering; sometimes compared to metformin	GI effects, drug interactions, variable product quality
Resveratrol	SIRT1/AMPK signaling; indirect mTOR effects	Human bioavailability and clinical endpoints weak
EGCG	AMPK and inflammatory signaling	Liver toxicity risk at high supplemental doses
Curcumin	Inflammatory signaling, AMPK hints	Bioavailability/formulation problems
Spermidine	Autophagy induction	Human outcomes still developing

Swipe table →

See Supplements and Nutraceuticals and NAD+ and Sirtuin Activators.

07Practical Notes

Baseline Labs Before Considering Either Drug

CBC with differential
CMP including liver enzymes and kidney function
Fasting glucose, fasting insulin, HbA1c
Lipid panel including ApoB if available
hs-CRP
B12, methylmalonic acid, homocysteine for metformin users
Optional: DEXA, VO₂max, grip strength, waist/height ratio, CGM trial

Decision Heuristics

Metformin fits best when insulin resistance, prediabetes, PCOS/metabolic syndrome, or high fasting insulin is present.
Rapamycin fits, if at all, as a clinician-supervised experiment in someone with excellent baseline health practices and willingness to monitor labs/side effects.
Neither substitutes for resistance training, protein adequacy, sleep regularity, sunlight/circadian alignment, dental health, or visceral-fat reduction.
Pause rapamycin around surgery, acute infection, non-healed wounds, or major tissue-repair protocols such as PRP and Stem Cell Therapies unless a clinician has a specific reason not to.

Red Flags Requiring Medical Oversight

eGFR <45 for metformin discussion; eGFR <30 generally contraindicated.
Active infection, recurrent mouth ulcers, poor wound healing, uncontrolled lipids/glucose for rapamycin.
Polypharmacy involving CYP3A4/P-gp modulators.
Pregnancy, breastfeeding, fertility treatment, pediatric use.

08Notes

The strongest rapamycin claim is “robustly extends lifespan in mice,” not “proven anti-aging drug in humans.” Keep this distinction explicit.
The strongest metformin claim is “safe, cheap, metabolically useful, and trial-worthy,” not “proven longevity drug for healthy people.”
Need a dedicated note on rapamycin dosing protocols if this library expands beyond overview-level treatment.
Track TAME status and any large rapamycin/rapalog prevention trials as they mature.
A major unresolved contradiction: nutrient-sensing inhibition may improve stress resistance while also potentially impairing adaptation, reproduction, wound healing, or athletic gains if mistimed.

What studies and practitioners report

Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.

Trial 5–10 mg/week · Rapamycin (PEARL) healthy adults 50–85, n=115 PMID 40188830
Trial 1,700 mg/day · Metformin (MASTERS) healthy adults 65+, during resistance training, n=94 PMID 31557380

09Connections

Neighborhood · 8 linked entriesOpen full map →

10Sources

Barzilai N et al. (2016). "Metformin as a Tool to Target Aging." Cell Metabolism . PMID: 27304507 . PMCID: PMC5943638 .PubMed 27304507 · PMC5943638
Harrison DE et al. (2009). "Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice." Nature . PMID: 19587680 .PubMed 19587680
Roark KM, Iffland PH. (2025). "Rapamycin for Longevity: Pros, Cons, and Future Perspectives." PMID: 40620657 .PubMed 40620657
Bannister CA et al. (2014). "Can People With Type 2 Diabetes Live Longer Than Those Without?" Diabetes Obesity and Metabolism . PMID: 25059505 .PubMed 25059505
Gandini S et al. (2014). "Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders." PMID: 24985407 .PubMed 24985407
Aliper A et al. (2017). "Towards Natural Mimetics of Metformin and Rapamycin." Aging . PMCID: PMC5723685 .PMC5723685
Kapahi P et al. (2019). "Is Rapamycin a Dietary Restriction Mimetic?" PMID: 30854544 .PubMed 30854544

11Entry history

15 Oct 2026